Amgen is a leader in biotechnology-based human therapeutics... Show more
AMGN saw its Momentum Indicator move above the 0 level on September 30, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 71 similar instances where the indicator turned positive. In of the 71 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 30, 2025. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
AMGN moved above its 50-day moving average on October 01, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for AMGN crossed bearishly below the 50-day moving average on August 29, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMGN broke above its upper Bollinger Band on October 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMGN entered a downward trend on September 30, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.598) is normal, around the industry mean (9.704). P/E Ratio (24.317) is within average values for comparable stocks, (24.419). Projected Growth (PEG Ratio) (0.959) is also within normal values, averaging (2.018). Dividend Yield (0.032) settles around the average of (0.027) among similar stocks. P/S Ratio (4.615) is also within normal values, averaging (3.548).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AMGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
BTGD | 46.48 | 0.98 | +2.15% |
STKd 100% Bitcoin & 100% Gold ETF | |||
RETL | 10.34 | 0.05 | +0.49% |
Direxion Daily Retail Bull 3X ETF | |||
COWZ | 57.82 | 0.13 | +0.23% |
Pacer US Cash Cows 100 ETF | |||
QAI | 33.72 | N/A | N/A |
NYLI Hedge Multi-Strategy Tracker ETF | |||
HYXF | 47.32 | -0.02 | -0.04% |
iShares ESG Advanced Hi Yld Corp Bd ETF |
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with ABBV. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then ABBV could also see price increases.
Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
---|---|---|---|---|
AMGN | 100% | +0.16% | ||
ABBV - AMGN | 59% Loosely correlated | -1.12% | ||
PFE - AMGN | 54% Loosely correlated | +1.07% | ||
NVS - AMGN | 53% Loosely correlated | +1.08% | ||
MRK - AMGN | 51% Loosely correlated | -0.36% | ||
GSK - AMGN | 49% Loosely correlated | -0.78% | ||
More |